GlassScriptPhysician profile
Katharine Hammond
NPI 1093754798
$2,816.34
in general payments reported to CMS, 2019-2025
35 companies · $215 in 2025
The $215 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $779 · 2022: $733 · 2023: $628 · 2024: $462 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,305.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $472.63 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $318.85 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $296.75 | 2021-2024 | Mounjaro, Jardiance |
| Astellas Pharma US INC | $167.38 | 2021-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $165.00 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $164.63 | 2021-2022 | |
| Abbvie INC. | $155.31 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $147.12 | 2021-2025 | Verquvo, Steglatro, Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.39 | 2021-2025 | Xifaxan |
| Pfizer INC. | $99.83 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $89.81 | 2021-2024 | Farxiga |
| Amgen INC. | $81.14 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $47.42 | 2023-2024 | Gemtesa |
| Biogen, INC. | $44.76 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $43.48 | 2022-2024 | Nuedexta |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $37.93 | 2022 | |
| Exact Sciences Corporation | $33.65 | 2023-2024 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $29.15 | 2024 | Fanapt, Hetlioz |
| Sanofi-Aventis U.S. LLC | $28.90 | 2021 | |
| Corium, LLC | $27.63 | 2023 | Azstarys |
| Axsome Therapeutics, INC. | $27.04 | 2024 | Auvelity |
| Sunovion Pharmaceuticals INC. | $25.89 | 2022 | |
| Evoke Pharma, INC. | $19.60 | 2024 | |
| Phathom Pharmaceuticals, INC. | $17.04 | 2024 | Voquezna |
| Radius Health, INC. | $16.71 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.66 | 2022 | |
| Corcept Therapeutics | $16.28 | 2024 | Korlym |
| Atricure, INC. | $15.89 | 2024 | |
| Xeris Pharmaceuticals, INC. | $14.92 | 2025 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $14.68 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.28 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $12.79 | 2022 | |
| Dexcom, INC. | $12.20 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.81 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katharine Hammond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.